Biotech Values

[DewDiligence]

>> does the advisory committe just vote up and down? Can't they recommend that more data is required - sort of equivalent to an 'approvable' letter? <<

Sure. My 25% estimate is a catchall for all negative or ambiguous outcomes from the panel meeting.

>> I also need to guess what the price of Eyetech shares would be after a bad meeting. Want to apply your backgammon reckoning skills to that number? <<

Because we are talking about an array of “bad” outcomes, there’s also a wide range for the effect on the stock price. My guess is that any outcome short of an unconditional recommendation for approval puts the stock near or below its $21 IPO price. JMHO